Vertex Pharmaceuticals is the world's leading biotechnology company in cystic fibrosis and one of the world's leading biotechnology companies.
Vertex Pharmaceuticals generated $12.0 billion in revenue in 2025, growing 9% year-over-year, driven by its CFTR modulator portfolio — TRIKAFTA/KAFTRIO, SYMDEKO, and the newly approved ALYFTREK — which collectively treat approximately 90% of cystic fibrosis patients with eligible mutations. Vertex's dominance in cystic fibrosis is effectively a monopoly — no competitive CFTR modulator has successfully challenged Vertex's clinical and commercial leadership in this disease. The company's pipeline diversification is creating new growth vectors: CASGEVY (exagamglogene autotemcel), the first approved CRISPR gene editing therapy for sickle cell disease and beta-thalassemia, co-developed with CRISPR Therapeutics, and JOURNAVX (suzetrigine), a first-in-class Nav1.8 inhibitor approved for moderate-to-severe acute pain.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and platform capabilities
• Latest products, pipeline, and R&D programs
• M&A and partnership activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management
Table of Contents
1. Executive Summary
2. Company Overview
3. Strategic Directions
4. Financial Performance
5. SWOT Analysis
6. Technological Know-How and Key Products
7. M&A and Partnerships
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. Vertex Pharmaceuticals — Key Financial Metrics 2023-2025
Table 2. Vertex Pharmaceuticals — Revenue by Product 2023-2025
Table 3. Vertex Pharmaceuticals — Revenue by Geography 2023-2025
Table 4. Vertex Pharmaceuticals — R&D Investment 2023-2025
Table 5. Vertex Pharmaceuticals — SWOT Analysis
Table 6. Vertex Pharmaceuticals — Key Products and Pipeline 2025
Table 7. Vertex Pharmaceuticals — M&A Activity 2020-2025
Table 8. Vertex Pharmaceuticals — Key Management 2025
Table 9. Vertex Pharmaceuticals — Strategic Priorities 2025-2030
